OPCH - Option Care Amedisys in pact to offer Krystal Biotech's skin disorder therapy
2023-05-24 06:53:50 ET
Infusion service provider Option Care Health ( NASDAQ: OPCH ) and home healthcare company Amedisys ( NASDAQ: AMED ) have joined hands to deliver and administer Vyjuvek, an FDA-approved therapy from Krystal Biotech ( NASDAQ: KRYS ) for the rare skin disorder dystrophic epidermolysis bullosa (DEB).
Option Care ( OPCH ) announced late Tuesday that Krystal Biotech ( KRYS ) had selected the company as part of a limited distribution specialty pharmacy network for Vyjuvek, a topical gene therapy.
To this end, Bannockburn, Illinois-based Option Care ( OPCH ), has partnered with Amedisys ( AMED ) to deliver and administer Vyjuvek to patients in professional healthcare and home settings.
In Early May, OPCH agreed to merge with Amedisys ( AMED ), valuing the Baton Rouge, Louisiana-based health service provider at more than $3B.
Last week, the FDA greenlighted Vyjuvek as a non-invasive treatment option for wounds in patients aged six months and older with DEB linked to a particular genetic mutation.
More on Option Care
For further details see:
Option Care, Amedisys in pact to offer Krystal Biotech’s skin disorder therapy